MRK241227P100000
- 0.72
- -0.46-38.98%
Merck & Co Newsroom
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025 -- Barrons.com
Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website
Dow Rallies 117 Points On Gains For NVIDIA Corp., UnitedHealth Stocks
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck Downgraded by BMO Over Keytruda Concerns
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Investing in Merck (NYSE:MRK) Three Years Ago Would Have Delivered You a 43% Gain
Merck & Co., Inc. (MRK) Is Attracting Investor Attention: Here Is What You Should Know
Express News | Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024...
Merck: Will Record Pretax Chg Relating to Upfront Payment of $588M, or 18c/Shr, in 4Q Results >MRK
Express News | Merck & Co Inc - to Record $588 Million Pre-Tax Charge in Q4 2024 Related to Agreement
Express News | Merck & Co Inc - Lanova Eligible for up to $2.7 Billion in Milestone Payments
Express News | Merck Closes Exclusive Global License Agreement for Lm-299, an Investigational Anti-Pd-1/Vegf Bispecific Antibody
Express News | BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105